{"product_id":"collegiumpharma","title":"Collegium Pharmaceutical: Distribution and Sourcing – Six Business Analyses","description":"\u003cdiv class=\"pb-bundle\" data-pestel-bundle=\"v1\"\u003e\n\u003cdiv class=\"pb-intro\"\u003e\n\u003cp class=\"pb-eyebrow\"\u003e2026 company context · Six strategic perspectives\u003c\/p\u003e\n\u003ch2 class=\"pb-title\"\u003eCollegium Pharmaceutical Strategy Analysis Bundle\u003c\/h2\u003e\n\u003cp class=\"pb-lead\"\u003eCollegium Pharmaceutical is presented here as Collegium Pharmaceutical, Inc., the SEC registrant matching the workbook name. The supplied company context concerns prescription pain-relief and opioid formulations, with commercial activity spanning clinician and payer education, formulary access, controlled-substance compliance and distribution. This makes portfolio choices closely connected to reimbursement, evidence communication, reliable supply and regulatory execution.\u003c\/p\u003e\n\u003cp class=\"pb-lead\"\u003eFor the quarter from April 1 to June 30, 2026, Collegium Pharmaceutical, Inc. reported revenue of USD 199,878,000 and a GAAP net loss of USD 15,051,000 in its \u003ca href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1267565\/000162828026053851\/\" target=\"_blank\" rel=\"noopener noreferrer\"\u003eSEC Form 10-Q filed August 6, 2026\u003c\/a\u003e. The figures frame useful questions about portfolio priorities, net revenue after access costs, and the operating resilience needed to support prescription flow.\u003c\/p\u003e\n\u003cdiv class=\"pb-formats\"\u003e\n\u003cspan class=\"pb-format\"\u003e\u003cspan class=\"pb-file-icon pb-file-icon--excel\" aria-hidden=\"true\"\u003e\u003c\/span\u003eExcel files with structured analysis frameworks\u003c\/span\u003e\u003cspan class=\"pb-format\"\u003e\u003cspan class=\"pb-file-icon pb-file-icon--word\" aria-hidden=\"true\"\u003e\u003c\/span\u003eWord files with detailed company analysis\u003c\/span\u003e\n\u003c\/div\u003e\n\u003cp class=\"pb-note\"\u003e\u003cstrong\u003eAbout the images:\u003c\/strong\u003e Each image is a brief summary preview. Your purchase includes the Excel frameworks and Word files with the detailed company analysis. The previews are not the complete downloadable products.\u003c\/p\u003e\n\u003cnav class=\"pb-nav\" aria-label=\"Explore the six analyses\"\u003e\u003ca href=\"#bcg\"\u003eBCG Matrix\u003c\/a\u003e\u003ca href=\"#canvas\"\u003eCanvas\u003c\/a\u003e\u003ca href=\"#five-forces\"\u003eFive Forces\u003c\/a\u003e\u003ca href=\"#marketing-mix\"\u003eMarketing Mix\u003c\/a\u003e\u003ca href=\"#pestel\"\u003ePESTLE\u003c\/a\u003e\u003ca href=\"#swot\"\u003eSWOT Analysis\u003c\/a\u003e\u003c\/nav\u003e\n\u003c\/div\u003e\n\n\u003cdiv id=\"bcg\" class=\"pb-row\" tabindex=\"-1\" aria-labelledby=\"pb-heading-bcg\"\u003e\n\u003cdiv class=\"pb-copy\"\u003e\n\u003cdiv class=\"pb-heading\"\u003e\n\u003cspan class=\"pb-icon pb-icon--bcg\" aria-hidden=\"true\"\u003e\u003c\/span\u003e\u003ch3 id=\"pb-heading-bcg\" class=\"pb-heading-title\"\u003eBCG Matrix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp class=\"pb-question\"\u003eWhich product areas should receive scarce commercial, access and supply-management attention?\u003c\/p\u003e\n\u003cp\u003eThe Collegium Pharmaceutical BCG Matrix helps examine a pain-management portfolio through the two defining criteria: market growth and relative market share. Rather than assigning any therapy to a quadrant without evidence, it provides a disciplined way to compare whether individual products may behave more like Stars, Cash Cows, Question Marks or Dogs. For a regulated prescription business, that comparison can connect demand opportunity with formulary conditions, lifecycle requirements, manufacturing attention and the resources needed to sustain responsible promotion.\u003c\/p\u003e\n\u003cul class=\"pb-list\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePortfolio logic.\u003c\/strong\u003e Compare relative share and market-growth assumptions before treating revenue contribution alone as a priority signal.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eResource trade-offs.\u003c\/strong\u003e Consider how payer access work, medical education, supply capacity and compliance effort could differ across product categories.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePlanning view.\u003c\/strong\u003e Use the Excel framework to map alternatives, then use the Word analysis to document the assumptions and questions behind each portfolio discussion.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv class=\"pb-outcome\"\u003e\n\u003cstrong\u003eWhat you can take away\u003c\/strong\u003e A clearer structure for discussing where commercial and operational resources may be concentrated, protected or reconsidered.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pb-visual\"\u003e\n\u003cspan data-pestel-preview=\"1\"\u003e\u003c\/span\u003e\u003cp class=\"pb-caption\"\u003eBCG Matrix summary preview. The full company analysis is provided in Excel and Word.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\n\u003cdiv id=\"canvas\" class=\"pb-row pb-row--reverse\" tabindex=\"-1\" aria-labelledby=\"pb-heading-canvas\"\u003e\n\u003cdiv class=\"pb-copy\"\u003e\n\u003cdiv class=\"pb-heading\"\u003e\n\u003cspan class=\"pb-icon pb-icon--canvas\" aria-hidden=\"true\"\u003e\u003c\/span\u003e\u003ch3 id=\"pb-heading-canvas\" class=\"pb-heading-title\"\u003eBusiness Model Canvas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp class=\"pb-question\"\u003eHow do access, clinical education, supply controls and net revenue fit together in one operating model?\u003c\/p\u003e\n\u003cp\u003eThe Collegium Pharmaceutical Business Model Canvas connects all nine building blocks: customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partnerships and cost structure. It helps relate clinicians, payers and other decision-makers to the company’s prescription-product value proposition, while testing how field activity, medical affairs, distribution, qualified manufacturing partners and regulated quality systems support that proposition. The lens is useful because formulary contracts, rebates and chargebacks can materially affect how gross demand becomes net economic value.\u003c\/p\u003e\n\u003cul class=\"pb-list\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccess pathway.\u003c\/strong\u003e Trace how payer engagement and utilization controls can influence whether a prescription reaches the patient pathway.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOperating dependencies.\u003c\/strong\u003e Link controlled-substance tracking, validated processes, release testing and external manufacturing relationships to dependable delivery.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eConnected model.\u003c\/strong\u003e Populate the Excel blocks for workshop discussion and use the Word analysis to explore the relationships and trade-offs between them.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv class=\"pb-outcome\"\u003e\n\u003cstrong\u003eWhat you can take away\u003c\/strong\u003e A joined-up view of how customer access, operational capabilities and revenue mechanics can reinforce or constrain one another.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pb-visual\"\u003e\n\u003cspan data-pestel-preview=\"2\"\u003e\u003c\/span\u003e\u003cp class=\"pb-caption\"\u003eBusiness Model Canvas summary preview. The full company analysis is provided in Excel and Word.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\n\u003cdiv id=\"five-forces\" class=\"pb-row\" tabindex=\"-1\" aria-labelledby=\"pb-heading-five-forces\"\u003e\n\u003cdiv class=\"pb-copy\"\u003e\n\u003cdiv class=\"pb-heading\"\u003e\n\u003cspan class=\"pb-icon pb-icon--five-forces\" aria-hidden=\"true\"\u003e\u003c\/span\u003e\u003ch3 id=\"pb-heading-five-forces\" class=\"pb-heading-title\"\u003ePorter's Five Forces\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp class=\"pb-question\"\u003eWhat industry pressures could influence economics in regulated prescription pain management?\u003c\/p\u003e\n\u003cp\u003eCollegium Pharmaceutical Porter's Five Forces organizes the pressures around rivalry, supplier power, buyer power, threat of new entrants and threat of substitutes. Payer and formulary decision-makers may hold meaningful buyer influence where coverage terms, rebates and utilization controls shape access. Supplier power can be examined through dependence on qualified contract manufacturers, analytical capability and controlled distribution requirements. Rivalry and entry barriers should be considered alongside the substantial regulatory and quality demands of prescription medicines, while substitutes include alternative ways to address pain-management needs rather than only direct pharmaceutical competitors.\u003c\/p\u003e\n\u003cul class=\"pb-list\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eBuyer leverage.\u003c\/strong\u003e Assess how contracting, access barriers and reimbursement negotiation may affect realized demand and net pricing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSupply leverage.\u003c\/strong\u003e Examine why validated partners, dual-sourcing options and quality controls matter when continuity is commercially important.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eForce comparison.\u003c\/strong\u003e Use the Excel grid to separate evidence and assumptions for each force, with the Word analysis supporting a fuller discussion of implications.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv class=\"pb-outcome\"\u003e\n\u003cstrong\u003eWhat you can take away\u003c\/strong\u003e A practical way to distinguish product-level competition from the wider payer, supplier, regulatory and substitute pressures around the business.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pb-visual\"\u003e\n\u003cspan data-pestel-preview=\"3\"\u003e\u003c\/span\u003e\u003cp class=\"pb-caption\"\u003ePorter's Five Forces summary preview. The full company analysis is provided in Excel and Word.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\n\u003cdiv id=\"marketing-mix\" class=\"pb-row pb-row--reverse\" tabindex=\"-1\" aria-labelledby=\"pb-heading-marketing-mix\"\u003e\n\u003cdiv class=\"pb-copy\"\u003e\n\u003cdiv class=\"pb-heading\"\u003e\n\u003cspan class=\"pb-icon pb-icon--marketing-mix\" aria-hidden=\"true\"\u003e\u003c\/span\u003e\u003ch3 id=\"pb-heading-marketing-mix\" class=\"pb-heading-title\"\u003eMarketing Mix (4Ps)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp class=\"pb-question\"\u003eHow should Product, Price, Place and Promotion be evaluated when prescribing and payer access both matter?\u003c\/p\u003e\n\u003cp\u003eThe Collegium Pharmaceutical Marketing Mix considers the four connected decisions of Product, Price, Place and Promotion in a highly regulated prescription setting. Product analysis can focus on the clinical and controlled-substance context that informs value communication. Price analysis can distinguish list-price logic from the effect of rebates, chargebacks and contract terms on net revenue. Place helps examine routes through distribution and dispensing pathways, while Promotion considers the coordinated roles of field sales, medical affairs, payer teams, digital engagement and key opinion leader education.\u003c\/p\u003e\n\u003cul class=\"pb-list\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct message.\u003c\/strong\u003e Test whether the value proposition is translated appropriately for prescribers, payer stakeholders and other relevant audiences.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNet economics.\u003c\/strong\u003e Compare pricing choices with access conditions instead of viewing volume, contract concessions and revenue realization separately.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExecution map.\u003c\/strong\u003e Use the Excel framework to align the four Ps and consult the Word analysis when recording channel, access and communication considerations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv class=\"pb-outcome\"\u003e\n\u003cstrong\u003eWhat you can take away\u003c\/strong\u003e A more coherent view of how product positioning, payer economics, distribution and compliant communication can work together.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pb-visual\"\u003e\n\u003cspan data-pestel-preview=\"4\"\u003e\u003c\/span\u003e\u003cp class=\"pb-caption\"\u003eMarketing Mix summary preview. The full company analysis is provided in Excel and Word.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\n\u003cdiv id=\"pestel\" class=\"pb-row\" tabindex=\"-1\" aria-labelledby=\"pb-heading-pestel\"\u003e\n\u003cdiv class=\"pb-copy\"\u003e\n\u003cdiv class=\"pb-heading\"\u003e\n\u003cspan class=\"pb-icon pb-icon--pestel\" aria-hidden=\"true\"\u003e\u003c\/span\u003e\u003ch3 id=\"pb-heading-pestel\" class=\"pb-heading-title\"\u003ePESTLE Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp class=\"pb-question\"\u003eWhich external changes could reshape access, compliance costs, demand conditions or supply planning?\u003c\/p\u003e\n\u003cp\u003eThe Collegium Pharmaceutical PESTLE analysis, also commonly called PESTEL, scans Political, Economic, Social, Technological, Legal and Environmental influences without treating possible developments as established facts. Political and legal questions include policy direction, FDA and DEA requirements, reimbursement rules and controlled-substance oversight. Economic conditions can affect payer behavior, contracting pressure and manufacturing costs. Social attitudes toward pain treatment, technological advances in quality or patient engagement, and environmental expectations around production and materials can each alter the context in which prescription products are supplied.\u003c\/p\u003e\n\u003cul class=\"pb-list\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePolicy watch.\u003c\/strong\u003e Separate a possible reimbursement or enforcement change from its potential implications for formulary access and compliance workload.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExternal signals.\u003c\/strong\u003e Consider how social expectations, manufacturing technology and supply-environment issues could affect future operating choices.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eScenario record.\u003c\/strong\u003e Use the Excel categories to prioritize outside signals and use the Word analysis to capture rationale, uncertainty and decision relevance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv class=\"pb-outcome\"\u003e\n\u003cstrong\u003eWhat you can take away\u003c\/strong\u003e An external-risk and opportunity agenda that supports more structured monitoring beyond immediate sales or financial results.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pb-visual\"\u003e\n\u003cspan data-pestel-preview=\"5\"\u003e\u003c\/span\u003e\u003cp class=\"pb-caption\"\u003ePESTLE Analysis summary preview. The full company analysis is provided in Excel and Word.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\n\u003cdiv id=\"swot\" class=\"pb-row pb-row--reverse\" tabindex=\"-1\" aria-labelledby=\"pb-heading-swot\"\u003e\n\u003cdiv class=\"pb-copy\"\u003e\n\u003cdiv class=\"pb-heading\"\u003e\n\u003cspan class=\"pb-icon pb-icon--swot\" aria-hidden=\"true\"\u003e\u003c\/span\u003e\u003ch3 id=\"pb-heading-swot\" class=\"pb-heading-title\"\u003eSWOT Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp class=\"pb-question\"\u003eHow can internal capabilities and constraints be weighed against the market conditions facing Collegium Pharmaceutical?\u003c\/p\u003e\n\u003cp\u003eThe Collegium Pharmaceutical SWOT analysis separates internal Strengths and Weaknesses from external Opportunities and Threats. Potential internal topics to assess include payer-facing capabilities, medical and commercial coordination, qualified manufacturing relationships, quality systems, redundancy planning and controlled-substance tracking. These should not be assumed to be proven strengths or weaknesses without evidence; the framework helps test them. External opportunities and threats can then be considered through formulary access, alternative treatments, evolving oversight, supplier conditions and broader attitudes toward pain management.\u003c\/p\u003e\n\u003cul class=\"pb-list\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eInternal reality.\u003c\/strong\u003e Evaluate capabilities and dependencies that management can influence, including commercial execution, quality assurance and supply resilience.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExternal context.\u003c\/strong\u003e Classify payer, regulatory, competitive and social developments as outside conditions rather than internal performance traits.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDecision synthesis.\u003c\/strong\u003e Use the Excel matrix to compare themes by quadrant and use the Word analysis to develop concise evidence-based discussion points.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv class=\"pb-outcome\"\u003e\n\u003cstrong\u003eWhat you can take away\u003c\/strong\u003e A balanced basis for connecting operational capabilities with external risks and potential strategic openings.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pb-visual\"\u003e\n\u003cspan data-pestel-preview=\"6\"\u003e\u003c\/span\u003e\u003cp class=\"pb-caption\"\u003eSWOT Analysis summary preview. The full company analysis is provided in Excel and Word.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\n\u003cdiv class=\"pb-closing\"\u003e\n\u003ch3\u003eSix lenses for a connected strategic discussion\u003c\/h3\u003e\n\u003cp\u003eUsed together, the six analyses let customers move from portfolio priorities and business-model mechanics to industry pressure, market execution, external change and internal-versus-external positioning. The Excel frameworks support structured comparison and workshop-ready thinking, while the detailed Word files provide company-specific context for developing more disciplined questions about Collegium Pharmaceutical’s access, supply, compliance and value-creation choices.\u003c\/p\u003e\n\u003cp class=\"pb-source\"\u003e\u003cstrong\u003eCompany background:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1267565\/000162828026053851\/\" target=\"_blank\" rel=\"noopener noreferrer\"\u003eCollegium Pharmaceutical, Inc. — SEC Form 10-Q filing, August 6, 2026\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097826759004,"sku":"collegiumpharma-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/collegiumpharma.webp?v=1790947059","url":"https:\/\/pestel-analysis.com\/products\/collegiumpharma","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}